Topotecan Hydrochloride Injection

Category: Chemotherapy / Antineoplastic agent
Form: Injectable solution for intravenous (IV) use

Uses:

• Treatment of small cell lung cancer (SCLC).

• Used in ovarian cancer, particularly in patients with relapsed or refractory disease.

• Sometimes used in other solid tumors based on oncologist’s discretion.

Mechanism of Action:

• Topotecan is a topoisomerase I inhibitor.

• It binds to the topoisomerase I-DNA complex, preventing re-ligation of single-strand DNA breaks during DNA replication.

• Accumulation of DNA damage leads to cell cycle arrest and apoptosis, primarily in rapidly dividing cancer cells.

Administration:

• Administered intravenously, typically over 30 minutes.

• Dosage depends on body surface area, type of cancer, prior therapies, and patient condition.

• Usually given in cycles with rest periods to allow normal cell recovery.

Side Effects:

• Hematologic: neutropenia, anemia, thrombocytopenia (bone marrow suppression).

• Gastrointestinal: nausea, vomiting, diarrhea, mucositis.

• Fatigue and weakness.

• Rare: hair loss, allergic reactions, liver enzyme elevation.

Precautions:

• Monitor complete blood counts (CBC) regularly to avoid severe myelosuppression.

• Adjust dose in renal or hepatic impairment.

• Use antiemetics to reduce nausea and vomiting.

• Avoid exposure to pregnant or breastfeeding women, as it can cause fetal harm.

• Ensure proper handling and disposal, as it is a cytotoxic drug.

Summary:
Topotecan Hydrochloride Injection is a chemotherapy drug that inhibits topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cancer cells. It is primarily used in small cell lung cancer and relapsed ovarian cancer. Administered intravenously in cycles, it requires careful monitoring of blood counts and supportive care due to potential myelosuppression, gastrointestinal side effects, and fatigue.